A survey conducted by the Lupus Research Alliance, which included 334 patients with lupus from 42 states, Washington, D.C., and Puerto Rico, found that 31% of those polled had difficulty obtaining hydroxychloroquine refills, while 5% of respondents couldn't get a refill amid the coronavirus pandemic. The shortages of hydroxychloroquine began in March after the drug was touted as being useful in preventing or treating COVID-19.
Hydroxychloroquine shortages affecting lupus patients
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.